Relay Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Atirmociclib in Combination with RLY-2608
Relay Therapeutics collaborates with Pfizer to evaluate a triplet combination of RLY-2608, atirmociclib, and fulvestrant in PI3Kα-mutated HR+/HER2- metastatic breast cancer patients, aiming for trial initiation by end of 2024. RLY-2608 is a mutant selective PI3Kα inhibitor, potentially benefiting over 250,000 patients annually in the U.S.
Reference News
Relay Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Atirmociclib in Combination with RLY-2608
Relay Therapeutics collaborates with Pfizer to evaluate a triplet combination of RLY-2608, atirmociclib, and fulvestrant in PI3Kα-mutated HR+/HER2- metastatic breast cancer patients, aiming for trial initiation by end of 2024. RLY-2608 is a mutant selective PI3Kα inhibitor, potentially benefiting over 250,000 patients annually in the U.S.